Pub Date : 2023-03-31DOI: 10.11648/j.jctr.20231101.11
Hayriye Şahinli, Esra Zeynelgil, O. Dogan, D. Yazılıtaş
: Background : Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods : A total of 60 patients with metastatic renal cell carcinoma were retrospectively evaluated between January 2014 and December 2020. Survival analyzes were performed with the Kaplan-Meier and log-rank tests. Results : Forty-six (76.7%) patients were male. Of the patients who received sunitinib, 22 patients (57.9%) were in the intermediate risk group, while 16 patients (42.1%) were in the poor risk group. Among patients receiving pazopanib, 14 patients (63.6%) were in the intermediate-risk group, while 8 patients (36.4%) were in the poor-risk group. There were no significant difference in the intermediate risk group of patients in terms of median progression-free survival between sunitinib and pazopanib (p=0.742). No significant differences were found in terms of progression-free survival in the high-risk group of patients (p=0.254). There were no significant differences in overall survival in the intermediate-risk group of patients receiving sunitinib or pazopanib (p = 0.377). There were no significant differences in terms of overall survival in the high-risk patient group receiving sunitinib or pazopanib (p = 0.3777). Conclusions: There were no significant difference in terms of progression-free survival and overall survival between the intermediate and poor-risk patient groups receiving pazopanib or sunitinib.
{"title":"Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center","authors":"Hayriye Şahinli, Esra Zeynelgil, O. Dogan, D. Yazılıtaş","doi":"10.11648/j.jctr.20231101.11","DOIUrl":"https://doi.org/10.11648/j.jctr.20231101.11","url":null,"abstract":": Background : Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods : A total of 60 patients with metastatic renal cell carcinoma were retrospectively evaluated between January 2014 and December 2020. Survival analyzes were performed with the Kaplan-Meier and log-rank tests. Results : Forty-six (76.7%) patients were male. Of the patients who received sunitinib, 22 patients (57.9%) were in the intermediate risk group, while 16 patients (42.1%) were in the poor risk group. Among patients receiving pazopanib, 14 patients (63.6%) were in the intermediate-risk group, while 8 patients (36.4%) were in the poor-risk group. There were no significant difference in the intermediate risk group of patients in terms of median progression-free survival between sunitinib and pazopanib (p=0.742). No significant differences were found in terms of progression-free survival in the high-risk group of patients (p=0.254). There were no significant differences in overall survival in the intermediate-risk group of patients receiving sunitinib or pazopanib (p = 0.377). There were no significant differences in terms of overall survival in the high-risk patient group receiving sunitinib or pazopanib (p = 0.3777). Conclusions: There were no significant difference in terms of progression-free survival and overall survival between the intermediate and poor-risk patient groups receiving pazopanib or sunitinib.","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91294621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01DOI: 10.11648/j.jctr.20221002.12
R. Fontes, J. Rodrigues, Camila Oliveira, Mauricio Peixoto, S. Doria, Rafael Silva, Sofia A Martins, J. Amorim, R. Nabiço, A. Marques
{"title":"Chemotherapy at the End of Life – The Reality of an Oncological Centre","authors":"R. Fontes, J. Rodrigues, Camila Oliveira, Mauricio Peixoto, S. Doria, Rafael Silva, Sofia A Martins, J. Amorim, R. Nabiço, A. Marques","doi":"10.11648/j.jctr.20221002.12","DOIUrl":"https://doi.org/10.11648/j.jctr.20221002.12","url":null,"abstract":"","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86442857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.11648/j.jctr.20221001.12
Paola Iturralde-Rosas Priego, Javier Gomezpedroso-Rea, Miguel Angel Mancera-Resendiz, Daniela Stuht-Lopez, Manuel Ubiergo-García
{"title":"Sentinel Lymph Node Biopsy Efficacy in Breast Cancer: A 4-year Experience Report","authors":"Paola Iturralde-Rosas Priego, Javier Gomezpedroso-Rea, Miguel Angel Mancera-Resendiz, Daniela Stuht-Lopez, Manuel Ubiergo-García","doi":"10.11648/j.jctr.20221001.12","DOIUrl":"https://doi.org/10.11648/j.jctr.20221001.12","url":null,"abstract":"","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85142614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Partial Reconstruction with Thigh Skin Graft for Penile Cancer: Case Presentation, Description of Surgical Technique and Literature Review","authors":"Lemme Gustavo Francisco, Rovegno Federico Agustin, Capiel Leandro, Rovegno Agustin Roberto","doi":"10.11648/j.jctr.20221002.11","DOIUrl":"https://doi.org/10.11648/j.jctr.20221002.11","url":null,"abstract":"","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80955246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An Evaluation of Pain Response Between Single Fraction Radiotherapy Versus 10 Fractions RT in Metastatic Vertebral Bone Disease: A Quasi Experimental Study","authors":"Bhaskar Chakraborty, Tarim Mahmood, Maksud Hassan Binoy","doi":"10.11648/j.jctr.20221001.11","DOIUrl":"https://doi.org/10.11648/j.jctr.20221001.11","url":null,"abstract":"","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82545585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-19DOI: 10.11648/J.JCTR.20210903.12
Jong-Hwa Lee, Joo-Yeon Gie, Y. Cho, C. Kim, Myung-Seup Chae, E. Kim, Wang-Jae Lee, U-Hyun Park, T. Lau, Josef Sotckenreiter, S. Woehrer, Karl Postbauer
SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important components, Pulsatilla saponin D is the most effective saponin with cancer cell apoptosis, deoxypodophyllotoxin inhibits new blood vessel formation, and anti-inflammatory effects with immune potentiative activities were confirmed. Cancer studied firstly in pancreas, followed by stomach, large intestine, lung, bile duct, liver, breast, kidney, uterus, oral cavity, esophagus and prostate. Almost of cancers were advanced and recurred status. Intravenous administration was done with intratumoral injection, intraperitoneal or intrathoracic administrations were done with change position, and inhalation therapy was also done. Side effects were clinically insignificant, most commonly fever, chills, nextly injection site pain, erythema, itching, nausea and vomitings were developed. 73.6% of total patients received 1-2 cycles of chemotherapies only, 3 cycles received patient survived for 6 months, 6 cycles survived for 12 months, and 9 cycles or more survived 30 months of survival durations. Pain control with improved appetite and immunity were noted as SB 365 treatments were going on. It is strongly requested to regain the permission of Korean FDA and prompt supports of the national medical insurance, that makes remarkable survival duration and for lesser economic burdons for advanced, recurrent cancer patients and save the funds of national medical insurance. And also highly recommended to make SB treatment available in foreign cancer patients for economic advantages and national image promotions.
{"title":"Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years","authors":"Jong-Hwa Lee, Joo-Yeon Gie, Y. Cho, C. Kim, Myung-Seup Chae, E. Kim, Wang-Jae Lee, U-Hyun Park, T. Lau, Josef Sotckenreiter, S. Woehrer, Karl Postbauer","doi":"10.11648/J.JCTR.20210903.12","DOIUrl":"https://doi.org/10.11648/J.JCTR.20210903.12","url":null,"abstract":"SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important components, Pulsatilla saponin D is the most effective saponin with cancer cell apoptosis, deoxypodophyllotoxin inhibits new blood vessel formation, and anti-inflammatory effects with immune potentiative activities were confirmed. Cancer studied firstly in pancreas, followed by stomach, large intestine, lung, bile duct, liver, breast, kidney, uterus, oral cavity, esophagus and prostate. Almost of cancers were advanced and recurred status. Intravenous administration was done with intratumoral injection, intraperitoneal or intrathoracic administrations were done with change position, and inhalation therapy was also done. Side effects were clinically insignificant, most commonly fever, chills, nextly injection site pain, erythema, itching, nausea and vomitings were developed. 73.6% of total patients received 1-2 cycles of chemotherapies only, 3 cycles received patient survived for 6 months, 6 cycles survived for 12 months, and 9 cycles or more survived 30 months of survival durations. Pain control with improved appetite and immunity were noted as SB 365 treatments were going on. It is strongly requested to regain the permission of Korean FDA and prompt supports of the national medical insurance, that makes remarkable survival duration and for lesser economic burdons for advanced, recurrent cancer patients and save the funds of national medical insurance. And also highly recommended to make SB treatment available in foreign cancer patients for economic advantages and national image promotions.","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89059759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-21DOI: 10.11648/j.jctr.20210902.12
K. Lin, C. Lengacher, Carmen Rodríguez, L. Szalacha, Jennifer R. Wolgemuth
Objectives: The major aims of this integrative review were to identify: 1) specific cognitive domains affected by chemotherapy; 2) predictors of cognitive dysfunction related to chemotherapy; 3) reported underlying mechanisms of chemotherapy-related cognitive dysfunction, and 4) clinical and research implications of chemotherapy-related cognitive dysfunction (CRCD) among breast cancer survivors. Methods: A computerized search of published research articles through the health journal databases of PubMed, CINAHL, EMBASE, and Web of Science was performed by using the keywords "chemotherapy," "cognitive dysfunction," "cognitive impairment," "cognitive decline," "breast cancer," and "breast carcinoma." References were screened according to inclusion and exclusion criteria. Results: After screening the titles and abstracts of 639 articles, 20 research studies were identified that focused on chemotherapy-related cognitive dysfunction in breast cancer for the final analysis. The 20 studies included: one longitudinal study, eleven prospective studies, two case-control studies, two retrospective studies, and four cross-sectional studies. The analysis of these 20 research studies contributed new knowledge about cognitive domains being affected by chemotherapy, risk factors for CRCD and underlying mechanisms of CRCD. Conclusion: This systematic review indicates significant clinical implications of early assessment and early interventions for CRCD to assist breast cancer survivors.
目的:本综合综述的主要目的是确定:1)受化疗影响的特定认知领域;2)化疗相关认知功能障碍的预测因素;3)化疗相关认知功能障碍的潜在机制;4)乳腺癌幸存者化疗相关认知功能障碍(CRCD)的临床和研究意义。方法:使用关键词“化疗”、“认知功能障碍”、“认知障碍”、“认知衰退”、“乳腺癌”和“乳腺癌”，通过PubMed、CINAHL、EMBASE和Web of Science等健康期刊数据库对已发表的研究文章进行计算机检索。根据纳入和排除标准筛选参考文献。结果:在筛选了639篇文章的标题和摘要后，确定了20项研究集中于化疗相关的乳腺癌认知功能障碍进行最终分析。这20项研究包括:1项纵向研究、11项前瞻性研究、2项病例对照研究、2项回顾性研究和4项横断面研究。对这20项研究的分析为化疗对认知领域的影响、CRCD的危险因素和CRCD的潜在机制提供了新的认识。结论:本系统综述提示早期评估和早期干预CRCD对乳腺癌幸存者有重要的临床意义。
{"title":"Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review","authors":"K. Lin, C. Lengacher, Carmen Rodríguez, L. Szalacha, Jennifer R. Wolgemuth","doi":"10.11648/j.jctr.20210902.12","DOIUrl":"https://doi.org/10.11648/j.jctr.20210902.12","url":null,"abstract":"Objectives: The major aims of this integrative review were to identify: 1) specific cognitive domains affected by chemotherapy; 2) predictors of cognitive dysfunction related to chemotherapy; 3) reported underlying mechanisms of chemotherapy-related cognitive dysfunction, and 4) clinical and research implications of chemotherapy-related cognitive dysfunction (CRCD) among breast cancer survivors. Methods: A computerized search of published research articles through the health journal databases of PubMed, CINAHL, EMBASE, and Web of Science was performed by using the keywords \"chemotherapy,\" \"cognitive dysfunction,\" \"cognitive impairment,\" \"cognitive decline,\" \"breast cancer,\" and \"breast carcinoma.\" References were screened according to inclusion and exclusion criteria. Results: After screening the titles and abstracts of 639 articles, 20 research studies were identified that focused on chemotherapy-related cognitive dysfunction in breast cancer for the final analysis. The 20 studies included: one longitudinal study, eleven prospective studies, two case-control studies, two retrospective studies, and four cross-sectional studies. The analysis of these 20 research studies contributed new knowledge about cognitive domains being affected by chemotherapy, risk factors for CRCD and underlying mechanisms of CRCD. Conclusion: This systematic review indicates significant clinical implications of early assessment and early interventions for CRCD to assist breast cancer survivors.","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80803918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-16DOI: 10.11648/j.jctr.20210902.11
Lopez Gonzalez Elga, Montero-Hurtado Francisco Manuel, Camacho Carrasco Maria
Objective: to find out the predictors in the recurrence of the illness in patients suffering from endometrium cancer at the differet stages of it. Material and Method: Retrospective study of 170 patients who were diagnosed with endometrium cancer between 2013-2017 at “Juan Ramon Jimenez” Hospital in Huelva. Variables such us age, degree of tumour differentation, miometrial invasion (MI), post surgical staging and lympho-vascular space infiltration (LVSI) were analysed in all those patients that had recurrences during the period of the study. The study was sone by using SPSS 23rd V. Once the analysis of Kolmorov-Smirnov concluded in an unusual result; the Chi-Squared test was used in order to obtain parametric categorical data; whereas the U (by Mann Whitney) test was used for the non-parametric data. P<0.01 was accepted as significant from a statistic point of view. results: During the study, 9 patients were diagnosed with tumoral affects recurrence. This means 5.3 % out of the whole sample. The statistic analysis concluded that there is no relation of dependence among the recurrence varible and the Miometrial Invasion variable (χ2=4.780,p=0.092) recurrence and Tumor grade (χ2=7.765, p=0.051) and recurrence and post surgical (χ2=10.200, p=0.070). On the contrary, it is stated that there is a relation of dependence among lymph-node damage variable and LSVI+(χ2=9.954, Cc=0.235, p<.01). The existence of LSVI was evaluated in all the patients. lVSI was negative in 141 cases and 4 of these cases had recurrence of the illness 55.5 % of the patients in which the illness recurred had positive LVSI (5 out of 9). Conclusions: our results proved that more than a half of the patients with recurrence of the illness have Lympho-vascular infiltration and also; if the LVSI is negative, there is a risk of 2.8% of having recurrence. Although it would be neccessary to carry out prospective multi-center studies, this preliminary study determines an obvious relation between LVSI and the recurrence in a short or long term period. Again, The variable that stablishes the LVSI can be a relevant datum when dealing with the staging process of the endometrium cancer, apart from being very useful in the prediction of the illness recurrence.
{"title":"Early Predictors of the Endometrium Cancer Recurrence in Our Environment","authors":"Lopez Gonzalez Elga, Montero-Hurtado Francisco Manuel, Camacho Carrasco Maria","doi":"10.11648/j.jctr.20210902.11","DOIUrl":"https://doi.org/10.11648/j.jctr.20210902.11","url":null,"abstract":"Objective: to find out the predictors in the recurrence of the illness in patients suffering from endometrium cancer at the differet stages of it. Material and Method: Retrospective study of 170 patients who were diagnosed with endometrium cancer between 2013-2017 at “Juan Ramon Jimenez” Hospital in Huelva. Variables such us age, degree of tumour differentation, miometrial invasion (MI), post surgical staging and lympho-vascular space infiltration (LVSI) were analysed in all those patients that had recurrences during the period of the study. The study was sone by using SPSS 23rd V. Once the analysis of Kolmorov-Smirnov concluded in an unusual result; the Chi-Squared test was used in order to obtain parametric categorical data; whereas the U (by Mann Whitney) test was used for the non-parametric data. P<0.01 was accepted as significant from a statistic point of view. results: During the study, 9 patients were diagnosed with tumoral affects recurrence. This means 5.3 % out of the whole sample. The statistic analysis concluded that there is no relation of dependence among the recurrence varible and the Miometrial Invasion variable (χ2=4.780,p=0.092) recurrence and Tumor grade (χ2=7.765, p=0.051) and recurrence and post surgical (χ2=10.200, p=0.070). On the contrary, it is stated that there is a relation of dependence among lymph-node damage variable and LSVI+(χ2=9.954, Cc=0.235, p<.01). The existence of LSVI was evaluated in all the patients. lVSI was negative in 141 cases and 4 of these cases had recurrence of the illness 55.5 % of the patients in which the illness recurred had positive LVSI (5 out of 9). Conclusions: our results proved that more than a half of the patients with recurrence of the illness have Lympho-vascular infiltration and also; if the LVSI is negative, there is a risk of 2.8% of having recurrence. Although it would be neccessary to carry out prospective multi-center studies, this preliminary study determines an obvious relation between LVSI and the recurrence in a short or long term period. Again, The variable that stablishes the LVSI can be a relevant datum when dealing with the staging process of the endometrium cancer, apart from being very useful in the prediction of the illness recurrence.","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86748718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-26DOI: 10.11648/j.jctr.20210901.12
Songbo Zhao, Chao Wu, Jialu Li, Yafen Li, Gangli An, Hui-min Meng, Zixuan Li, Lin Yang
Multiple myeloma (MM) is a malignancy characterized by abnormal proliferation of clonal plasma cells, and it is the second most common hematologic malignancy in the world after non-Hodgkin lymphoma. In recent years, significant progress has been made in the clinical treatment of MM. In particular, certain novel drugs, such as bortezomib, lenalidomide, and carfilzomib, have greatly improved the survival rate of patients with MM. However, because of drug resistance, most MM patients eventually suffer a relapse and die of the disease. In this study, the chimeric antigen receptor-modified T cell (CAR-T cell) technology, which has achieved success in recent clinical trials for B-cell acute lymphoblastic leukemia (B-ALL), was used. In view of the high CD138 expression in MM cells and the presence of the CD138–/CD19+ phenotype in a small subset of MM cells, and based on preliminary findings of effective killing of MM cells by CD19-CAR-T cells in clinical studies, CD138- and CD19-directed CAR-T cells were constructed. Through in vitro experiments and the use of a mouse model, we proved that these two types of CAR-T cells possess strong biological activity in the specific killing of target cells, and that the concomitant use of these cells significantly enhances the killing effect in an MM mouse model.
{"title":"Concomitant Use of CD138- and CD19-directed Chimeric Antigen Receptor-modified T Cells Enhances Cytotoxicity Towards Multiple Myeloma","authors":"Songbo Zhao, Chao Wu, Jialu Li, Yafen Li, Gangli An, Hui-min Meng, Zixuan Li, Lin Yang","doi":"10.11648/j.jctr.20210901.12","DOIUrl":"https://doi.org/10.11648/j.jctr.20210901.12","url":null,"abstract":"Multiple myeloma (MM) is a malignancy characterized by abnormal proliferation of clonal plasma cells, and it is the second most common hematologic malignancy in the world after non-Hodgkin lymphoma. In recent years, significant progress has been made in the clinical treatment of MM. In particular, certain novel drugs, such as bortezomib, lenalidomide, and carfilzomib, have greatly improved the survival rate of patients with MM. However, because of drug resistance, most MM patients eventually suffer a relapse and die of the disease. In this study, the chimeric antigen receptor-modified T cell (CAR-T cell) technology, which has achieved success in recent clinical trials for B-cell acute lymphoblastic leukemia (B-ALL), was used. In view of the high CD138 expression in MM cells and the presence of the CD138–/CD19+ phenotype in a small subset of MM cells, and based on preliminary findings of effective killing of MM cells by CD19-CAR-T cells in clinical studies, CD138- and CD19-directed CAR-T cells were constructed. Through in vitro experiments and the use of a mouse model, we proved that these two types of CAR-T cells possess strong biological activity in the specific killing of target cells, and that the concomitant use of these cells significantly enhances the killing effect in an MM mouse model.","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79427444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-10DOI: 10.11648/J.JCTR.20210901.11
Moges Ayalew Kassaw, Eninur Dejen Amera, K. Azanaw
Background: Hepatitis is a contagious liver disease caused by Hepatitis B virus. When a pregnant mother infected, the Hepatitis B virus can stay in the body and Vertical transmit to baby and develop chronic liver disease. In regarding to this Neonatal immunization interrupts this vertical transmission and used to take preventive action. For that reason, this study was undertaken with the aim of determine the magnitude and predisposing factors of HBV infections among pregnant women. An institutional based cross-sectional study was conducted 333 pregnant women attending ANC from September 2020 to November 2020 at Debre Tabor Referral Hospital antenatal care clinic. Appropriate sample was collected; serum separated and tested with ELISA test for the detection of HBsAg. Fishers exact test was employed to see the association between variables as well as Logistic regression were applied to identify potential risk factors (P-value < 0.05) was considered as statistically significant. A total of 333 pregnant women within 100% response rate; were enrolled in this study and the magnitude of HBV infections found to be were (22.2%). among the potential risk factors multiple sexual behavior (AOR 3.096), 95% CI=1.469-6.525, P-value=0.003), shaving habit (AOR 3.375, 95% CI=1.511-7.538, P-value=0.003), a history of needle stick injury (AOR 4.080, 95% CI=2.041-8.156, P-value=0.000), history of common usage of Sharpe materials (AOR 8.229, 95% CI=3.991-16.967, P-value=0.000) and history of home delivery by traditional attendants were (AOR 1.557, 95% CI=0.621-3.899, P-value=0.000) were significantly associated with important predictors of hepatitis B infection. For that reason this study showed high endemicity of HBV infection among pregnant women. Multiple sexual practices, history of home delivery, needle stick injury, common usage of Sharpe materials and shaving habit were major factors for hepatitis B virus transmission. Thus, scaling up of screening pregnant women for HBV infection and provision of health education about risk factors and testing all pregnant mothers for hepatitis B virus should be a regular feature of the ANC service. Other community studies, as well as screening HBV antigen marker conducting, will play an important role in accurately determining the true spread of hepatitis B virus in the general population.
{"title":"Magnitude and Associated Risk Factor of HBV Virus Among Pregnant Mothers Attending Antenatal Care in Debre Tabor Referral Hospital; Northwest Ethiopia","authors":"Moges Ayalew Kassaw, Eninur Dejen Amera, K. Azanaw","doi":"10.11648/J.JCTR.20210901.11","DOIUrl":"https://doi.org/10.11648/J.JCTR.20210901.11","url":null,"abstract":"Background: Hepatitis is a contagious liver disease caused by Hepatitis B virus. When a pregnant mother infected, the Hepatitis B virus can stay in the body and Vertical transmit to baby and develop chronic liver disease. In regarding to this Neonatal immunization interrupts this vertical transmission and used to take preventive action. For that reason, this study was undertaken with the aim of determine the magnitude and predisposing factors of HBV infections among pregnant women. An institutional based cross-sectional study was conducted 333 pregnant women attending ANC from September 2020 to November 2020 at Debre Tabor Referral Hospital antenatal care clinic. Appropriate sample was collected; serum separated and tested with ELISA test for the detection of HBsAg. Fishers exact test was employed to see the association between variables as well as Logistic regression were applied to identify potential risk factors (P-value < 0.05) was considered as statistically significant. A total of 333 pregnant women within 100% response rate; were enrolled in this study and the magnitude of HBV infections found to be were (22.2%). among the potential risk factors multiple sexual behavior (AOR 3.096), 95% CI=1.469-6.525, P-value=0.003), shaving habit (AOR 3.375, 95% CI=1.511-7.538, P-value=0.003), a history of needle stick injury (AOR 4.080, 95% CI=2.041-8.156, P-value=0.000), history of common usage of Sharpe materials (AOR 8.229, 95% CI=3.991-16.967, P-value=0.000) and history of home delivery by traditional attendants were (AOR 1.557, 95% CI=0.621-3.899, P-value=0.000) were significantly associated with important predictors of hepatitis B infection. For that reason this study showed high endemicity of HBV infection among pregnant women. Multiple sexual practices, history of home delivery, needle stick injury, common usage of Sharpe materials and shaving habit were major factors for hepatitis B virus transmission. Thus, scaling up of screening pregnant women for HBV infection and provision of health education about risk factors and testing all pregnant mothers for hepatitis B virus should be a regular feature of the ANC service. Other community studies, as well as screening HBV antigen marker conducting, will play an important role in accurately determining the true spread of hepatitis B virus in the general population.","PeriodicalId":93775,"journal":{"name":"Journal of cancer treatment and research","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84460150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：